Mechanisms of multidrug resistance in cancer chemotherapy

K Bukowski, M Kciuk, R Kontek - International journal of molecular …, 2020 - mdpi.com
Cancer is one of the main causes of death worldwide. Despite the significant development of
methods of cancer healing during the past decades, chemotherapy still remains the main …

Cisplatin: The first metal based anticancer drug

S Ghosh - Bioorganic chemistry, 2019 - Elsevier
Abstract Cisplatin or (SP-4-2)-diamminedichloridoplatinum (II) is one of the most potential
and widely used drugs for the treatment of various solid cancers such as testicular, ovarian …

Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway

J Zhang, CM Simpson, J Berner, HB Chong, J Fang… - Cell, 2023 - cell.com
Multiple anticancer drugs have been proposed to cause cell death, in part, by increasing the
steady-state levels of cellular reactive oxygen species (ROS). However, for most of these …

New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment

SH Chen, JY Chang - International journal of molecular sciences, 2019 - mdpi.com
Although cisplatin has been a pivotal chemotherapy drug in treating patients with various
types of cancer for decades, drug resistance has been a major clinical impediment. In …

Biomarker-guided development of DNA repair inhibitors

JM Cleary, AJ Aguirre, GI Shapiro, AD D'Andrea - Molecular cell, 2020 - cell.com
Anti-cancer drugs targeting the DNA damage response (DDR) exploit genetic or functional
defects in this pathway through synthetic lethal mechanisms. For example, defects in …

PRMTs and arginine methylation: cancer's best-kept secret?

J Jarrold, CC Davies - Trends in molecular medicine, 2019 - cell.com
Post-translational modification (PTM) of proteins is vital for increasing proteome diversity
and maintaining cellular homeostasis. If the writing, reading, and removal of modifications …

Cisplatin in ovarian cancer treatment—known limitations in therapy force new solutions

A Zoń, I Bednarek - International journal of molecular sciences, 2023 - mdpi.com
Cisplatin is one of the most commonly used anticancer drugs worldwide. It is mainly used in
the treatment of ovarian cancer, but also used in testicular, bladder and lung cancers. The …

Targeted nanomedicine in cisplatin-based cancer therapeutics

Y Han, P Wen, J Li, K Kataoka - Journal of Controlled Release, 2022 - Elsevier
Since its license in 1978, cisplatin has proved to be one of the most successful
chemotherapeutic agents in the world. However, two acute challenges facing cisplatin …

A highly annotated database of genes associated with platinum resistance in cancer

D Huang, SR Savage, AP Calinawan, C Lin, B Zhang… - Oncogene, 2021 - nature.com
Platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin, is prescribed
to 10-20% of all cancer patients. Unfortunately, platinum resistance develops in a significant …